Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-240 Study for 1L Advanced Hepatocellular Carcinoma (HCC)

Shots:

• The P-III KEYNOTE-240 Study involves assessing of Keytruda (200mg, q3w) vs PBO in 413 patients with 1L advance HCC
• The study resulted in unmet 1EPs & 2EPs as OS, PFS & ORR, DOR, disease control rate and time to progression respectively in the trial
• Keytruda (pembrolizumab) 100mg IV is a mAb, used as an anti-D-L1 therapy that blocks the interaction between PD-1 and its ligands i.e PD-L1 & PD- L2, further activating T lymphocytes

Click here to read full press release/ article| Ref: Merck| Image: Twitter